Combination Antifungal Therapy in Treatment of Murine Pulmonary Mucormycosis: Roles of Quinolones and Azoles | Zendy

Alan M. Sugar | Zendy; Xiuping Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination Antifungal Therapy in Treatment of Murine Pulmonary Mucormycosis: Roles of Quinolones and Azoles

Author(s) -

Alan M. Sugar,

Xiuping Liu

Publication year - 2000

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.44.7.2004-2006.2000

Subject(s) - trovafloxacin , fluconazole , mucormycosis , amphotericin b , ciprofloxacin , mycosis , combination therapy , medicine , pharmacology , azole , microbiology and biotechnology , antibiotics , antifungal , biology , immunology , dermatology , surgery

Amphotericin B is the only recognized antifungal used in the treatment of mucormycosis. In this study, we evaluated various combinations of amphotericin B, fluconazole, and trovafloxacin or ciprofloxacin in the treatment of murine pulmonary mucormycosis. The combination of fluconazole and a quinolone has a marked effect on the outcome of murine pulmonary mucormycosis. Even though we did not optimize therapy with the drugs, these experiments suggest that azoles, especially fluconazole, in combination with either trovafloxacin or ciprofloxacin were effective in the treatment of this aggressive mycosis in the mouse model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research